Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025

Arbutus Biopharma Corp

In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.
3 patients in nivolumab cohort achieved HBsAg loss and seroconversion at week 48.
AB-101 Phase 1a/1b Part 3: 10mg once daily for 28 days well tolerated with PD-L1 receptor occupancy similar to healthy volunteers; no liver dysfunction.
Across all imdusiran Phase 2a trials, 8 patients functionally cured, 7 with baseline HBsAg <1000 IU/mL.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.